LearnGlossaryMarketStocksSuperinvestorsSign in

BVS

Bioventus Inc.

Healthcare · $925M market cap

Verdict

Share price

$13.13

close of Oct 3, 2026

Fair value

$6.45

Sticker Price

Payback Price

$2.58

buy price

Overpriced

BVS is Overpriced: at $13.13 it trades 103% above its fair value of $6.45. Its buy price (Payback Price) is $2.58, 80% below today's price. Business quality is limited: only 1 of 5 key numbers clears the 10% bar.

How we valued it

Buffett Normalized. A profitable, growing business, so we project its earnings 10 years ahead and work out what that is worth today.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-18.9% a year✗
Sales growth8.5% a year✗
Free cash flow growth14.1% a year✓
Return on invested capital-1.2%✗

Follow BVS

Get notified when it reaches its buy price of $2.58. Free.

Create a free account

About Bioventus Inc.

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to…

Medical - Devices

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works